Don't miss

Replay


LATEST SHOWS

FOCUS

Catalonia's pro-independence movement tempted by radicalisation

Read more

ENCORE!

Film show: 'May ’68', Director’s Fortnight reloaded, 'A Paris Education'

Read more

IN THE PRESS

Macron and Trump: Dandruff diplomacy?

Read more

PERSPECTIVE

Big data: ‘A key democratic issue’

Read more

MIDDLE EAST MATTERS

Susan Meiselas: Kurdistan through the lens

Read more

BUSINESS DAILY

Global wine production drops to lowest level in 60 years

Read more

MEDIAWATCH

Trump and Macron media moments in the US

Read more

ENCORE!

Photographer Clare Strand explores the causes and consequences of communication breakdown

Read more

IN THE PRESS

Fashion and ethics: Five years after Bangladesh factory collapse, what's changed?

Read more

Asia-pacific

First case of Tamiflu-resistant H1N1 is reported

Text by NEWS WIRES

Latest update : 2009-07-03

Hong Kong's health department has detected a case of the human swine influenza virus that is resistant to Tamiflu, the main antiviral flu drug. Only two other cases of Tamiflu-resistant H1N1 have been found so far, in Denmark and Japan.

Reuters - Hong Kong's health department said on Friday it had detected a case of human swine influenza virus that was resistant to Tamiflu, the main antiviral flu drug.

 

The World Health Organisation has declared a pandemic is under way from the new H1N1 virus, also known as swine flu.

 

"This is the first time Tamiflu resistance in HSI virus (was) found in Hong Kong," a spokesman for the health department said in a statement.

 

Only two other cases of Tamiflu-resistant H1N1 have been found so far, in Denmark and Japan.

 

According to the statement, the virus was isolated from a specimen taken from a 16-year-old girl coming from San Francisco, who was taken in by the Port Health Office at the Hong Kong International Airport upon arrival on June 11.

 

The virus was identified during the health department's routine sensitivity test of HSI virus to oseltamivir and zanamivir, the spokesman said.

 

Tamiflu, a tablet known generically as oseltamivir, is made by Switzerland's Roche AG and Gilead Sciences, while Relenza, an inhaled drug known generically as zanamivir, is made by GlaxoSmithKline under licence from Australia's Biota Inc

 

The department said that tests showed that the strain was sensitive to zanamivir.

 

Resistance to Tamiflu has been previously documented in the deadly bird flu virus H5N1 and seasonal H1N1 flu.

 

"You can always expect a certain number of resistances," said Roche spokeswoman Claudia Schmitt. "It does not necessarily mean that the strain is resistant to Tamiflu."

 

Date created : 2009-07-03

COMMENT(S)